US Pharma MarketingVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators
Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Vincentage Pharma’s oral GLP-1 agonist has been tied to mean weight loss of 12.4% over a year, setting up the biotech to pursue Eli Lilly’s orforglipron to Chinese regulators.
Source: FierceBiotech